Loading
A phase 2 trial of RV001V in prostate cancer, run by RhoVac APS, active and no longer recruiting.
Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer is a phase 2 interventional study registered as NCT04114825 by RhoVac APS, with 180 participants enrolled, started 2019-11-19 and due to reach its primary completion in 2022-04. Interventions recorded: RV001V.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/